IRON vs AB Comparison

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

AllianceBernstein provides investment management services to institutional (42% of assets under management), retail (40%), and private (18%) clients through products that include mutual funds, hedge funds, and separately managed accounts. At the end of July 2026, the company had $909.0 billion in managed assets, composed primarily of fixed-income (35% of AUM) and equity (40%) strategies, with other investments (including asset allocation services and certain other alternative investments) accounting for the remainder.